Biotest clinical trials
Acquired by Grifols, Apr 25, 2022 · source ↗
The registry lists 14 studies whose lead sponsor is Biotest. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 14, 2026.
Before and after it joined Grifols
- First submitted before Biotest became part of Grifols
- 12
- First submitted after Biotest became part of Grifols
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Biotest14 studies
Something wrong with this grouping? Tell us on the Grifols page.
Studies
Recruiting first, then most recently updated. Showing 14 of 14. All Grifols studies →
- Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)RecruitingNCT05722938Phase 3
Sponsor listed in the registry: Biotest · First submitted after Biotest became part of Grifols
- Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen DeficiencyCompletedNCT02065882Phase 3
Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols
- Adjusted Fibrinogen Replacement StrategyCompletedNCT03444324Phase 3
Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols
- Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 PneumoniaTerminatedNCT05531149Phase 3
Sponsor listed in the registry: Biotest · First submitted after Biotest became part of Grifols
- Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)TerminatedNCT05170269Phase 3
Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols
- Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PIDCompletedNCT02810444Phase 3
Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols
- Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19CompletedNCT04576728Phase 2
Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols
- Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus ErythematosusCompletedNCT02554019Phase 2
Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols
- This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)CompletedNCT02859909Phase 3
Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols
- Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid ArthritisTerminatedNCT01999192Phase 2
Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols
- Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAPCompletedNCT01420744Phase 2
Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols
- A Clinical Trial of Zutectra in Patients Who Recently Received a Liver TransplantCompletedNCT01856413Phase 3
Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols
- Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)CompletedNCT01481493Phase 2
Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols
- Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT01072383Phase 2
Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols